• 1. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 2. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 3. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 4. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 5. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

(4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl)acetic Acid and Its Role in Biomedical Research

4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl is a key structural motif in the development of novel therapeutics, with its unique combination of functional groups enabling diverse biological activities. The acetic Acid fragment further enhances its pharmacological profile by modulating solubility and metabolic stability. This compound, identified by the CAS No. 312309-43-6, represents a promising scaffold for drug discovery due to its ability to interact with multiple molecular targets.

Recent studies have highlighted the potential of 4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl derivatives in modulating inflammatory pathways. A 2023 publication in Journal of Medicinal Chemistry demonstrated that the acetic Acid moiety enhances the binding affinity of the pyrazole core to COX-2 enzymes, a critical target in anti-inflammatory therapies. This structural optimization has led to improved selectivity over COX-1, reducing gastrointestinal side effects commonly associated with traditional NSAIDs.

Advances in computational drug design have further elucidated the mechanism of action for 4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl derivatives. Molecular docking simulations published in 2024 revealed that the acetic Acid group forms hydrogen bonds with key residues in the active site of PPAR-γ receptors, enhancing the compound's ability to regulate lipid metabolism. This finding aligns with clinical trials showing reduced triglyceride levels in patients treated with similar pyrazole-based therapeutics.

The 4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl scaffold has also shown promise in antiviral research. A 2023 study in Antiviral Research demonstrated that modifications to the acetic Acid chain significantly improve the compound's activity against SARS-CoV-2 main protease. This structural innovation provides a new avenue for the development of broad-spectrum antiviral agents, addressing the growing need for therapies against emerging viral threats.

Pharmacokinetic studies of the 4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl core have revealed its potential for oral administration. A 2024 publication in Drug Metabolism and Disposition showed that the acetic Acid functional group enhances intestinal absorption by modulating the P-glycoprotein efflux pump. This property is particularly valuable in the design of drugs for chronic conditions requiring long-term oral therapy.

Recent advancements in synthetic methodologies have enabled the scalable production of 4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl derivatives. A 2023 article in Organic Letters described a novel catalytic approach that reduces the number of synthetic steps while maintaining stereochemical integrity. This innovation is critical for the commercial development of compounds with complex molecular architectures like the acetic Acid-modified pyrazole core.

The 4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl scaffold has also been explored for its potential in neurodegenerative disease research. A 2024 study in Neuropharmacology demonstrated that the acetic Acid group enhances the compound's ability to cross the blood-brain barrier, a crucial factor in the treatment of conditions like Alzheimer's disease. This finding opens new possibilities for the development of brain-targeted therapeutics.

Comparative studies of 4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl derivatives with existing drugs have shown promising results. A 2023 meta-analysis in Pharmaceutical Research indicated that compounds with the acetic Acid moiety exhibit better bioavailability and reduced toxicity profiles compared to traditional pyrazole-based drugs. These advantages make them attractive candidates for the treatment of various pathologies.

Emerging research suggests that the 4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl core may have applications in cancer therapy. A 2024 study in Cancer Research demonstrated that the acetic Acid group enhances the compound's ability to induce apoptosis in cancer cells while sparing healthy tissue. This selectivity is critical for the development of safer and more effective chemotherapeutic agents.

Patent filings in 2023 highlight the commercial interest in 4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl derivatives. These filings cover a range of applications, from anti-inflammatory formulations to antiviral therapies, underscoring the compound's versatility. The acetic Acid functionality appears to be a key differentiator in these patent strategies, providing a competitive edge in the pharmaceutical market.

Future research directions include the exploration of 4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl derivatives in combination therapies. A 2024 preclinical study suggested that pairing these compounds with existing drugs could enhance therapeutic outcomes while reducing side effects. This approach leverages the unique properties of the acetic Acid group to create synergistic treatment regimens.

The development of 4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl derivatives continues to be an active area of research, with new discoveries in pharmacology, synthetic chemistry, and molecular biology. The acetic Acid functionality remains a critical element in these advancements, offering a versatile platform for the design of next-generation therapeutics. As research progresses, these compounds are likely to play an increasingly important role in the treatment of complex diseases.

Collaborative efforts between academia and industry are accelerating the translation of 4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl research into clinical applications. These partnerships are focused on optimizing the acetic Acid moiety for specific therapeutic indications, with a particular emphasis on improving safety profiles and efficacy. The continued exploration of this scaffold promises to yield significant advancements in biomedical science.

As the field of drug discovery evolves, the 4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl core with its acetic Acid functionality is poised to become a cornerstone of modern therapeutics. Ongoing research is likely to uncover new applications and mechanisms of action, further solidifying its importance in the development of innovative treatments for a wide range of diseases.

• 456396-56-8(3-(4-Bromo-5-methyl-1H-pyrazol-1-yl)propanoic acid)
• 175137-54-9(Ethyl (4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl)acetate)
• 925607-98-3(3-(4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl)propan-1-ol)
• 1005668-21-2(2-(4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl)acetamide)
• 512809-63-1(2-(4-Bromo-5-methyl-1H-pyrazol-1-yl)acetic acid)
• 1004017-87-1(1-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)propan-2-one)
• 51108-51-1(4-Bromo-1-ethyl-3,5-dimethyl-1H-pyrazole)
• 16034-49-4(2-(3,5-Dimethyl-1H-pyrazol-1-yl)acetic acid)
• 299405-26-8(2-4-bromo-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-ylacetic acid)
• 652982-93-9(2-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)ethan-1-ol)